Medpace (MEDP) Rule 144 Filing — 38,013 Shares Proposed Sale

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) Form 144 summary: This notice reports a proposed sale of 38,013 common shares through UBS Financial Services on 08/27/2025. The filing lists an aggregate market value of $180,560,175 for the shares and shows 28,741,609 shares outstanding for the issuer. The shares were acquired by the seller on 02/15/2022 through an option exercise, with payment completed in cash on 03/01/2022. The filing also discloses a sale during the past three months: 48,487 shares sold on 07/28/2025 for $21,900,851. The form includes the standard signature representation that the seller is not aware of undisclosed material adverse information.

Positive

• Disclosure compliance: The filing documents the proposed sale under Rule 144, including broker, dates, and amounts.
• Clear acquisition history: Shares were acquired by option exercise on 02/15/2022 with cash payment on 03/01/2022, which is explicitly stated.
• Prior sale disclosed: A sale of 48,487 shares on 07/28/2025 for $21,900,851 is reported, providing transparency on recent insider transactions.

Negative

• Insider selling activity: The filer reports a proposed sale of 38,013 shares and a recent sale of 48,487 shares within the past three months, which may be interpreted by some investors as increased insider selling.
• Limited context: The form contains no information about the seller's reasons for the sale or any company operational developments; only the required Rule 144 disclosures are provided.

Insights

Securities Analyst

TL;DR: Routine Rule 144 insider sale notice; documents acquisition by option exercise and a recent prior sale.

The filing is a standard Rule 144 notice documenting a proposed sale of 38,013 common shares via UBS and confirming the shares were acquired by option exercise in February 2022 with cash payment in March 2022. The disclosure of a prior sale of 48,487 shares in July 2025 provides context on recent insider activity. For investors, this is procedural disclosure required by securities law rather than an operational update from the company.

Corporate Governance Expert

TL;DR: Compliance-focused filing showing insider sale mechanics and the seller's certification about material nonpublic information.

The form includes the required representation that the seller is not aware of undisclosed material adverse information and notes the method of acquisition (option exercise) and cash payment. The presence of a recent sale within the past three months is disclosed, which is relevant for aggregation rules under Rule 144. The filing appears to follow procedural disclosure norms; no governance irregularities are indicated by the content provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	38013	180560175	28741609	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/15/2022	Option Exercise	Issuer			38013	03/01/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
August J. Troendle 5375 Medpace Way Cincinnati OH 45227	Common	07/28/2025	48487	21900851

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the MEDP Form 144 report?

The filing reports a proposed sale of 38,013 common shares via UBS Financial Services with an aggregate market value listed as $180,560,175, and confirms a prior sale of 48,487 shares on 07/28/2025 for $21,900,851.

When were the shares being sold by the insider acquired?

The shares were acquired by the seller on 02/15/2022 through an option exercise, with payment made in cash on 03/01/2022.

Through which broker will the MEDP shares be sold?

The proposed sale lists UBS Financial Services Inc, located at 1000 Harbor Blvd, Weehawken, NJ, as the broker.

How many shares does Medpace report outstanding in this filing?

The filing reports 28,741,609 shares outstanding for the issuer.

Does the filing state whether the seller knows of any undisclosed material information?

Yes. By signing the notice, the seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

Was there recent insider selling reported in the past three months?

Yes. The filing discloses a sale of 48,487 shares on 07/28/2025 with gross proceeds of $21,900,851.